Core Viewpoint - The collaboration between Heng Rui Medicine and Merck marks a significant licensing agreement in the innovative drug sector, indicating a trend of increasing partnerships between multinational pharmaceutical companies and local biotech firms in China [1][2]. Group 1: Licensing Agreements - Heng Rui Medicine announced a licensing agreement with Merck for the oral small molecule project Lp(a), granting Merck exclusive rights to develop, produce, and commercialize the compound HRS-5346 outside Greater China [1]. - Merck will pay Heng Rui a $200 million upfront fee, with potential milestone payments related to development, regulatory, and commercialization reaching up to $1.77 billion [1]. - Heng Rui will also receive sales royalties based on the performance of HRS-5346 outside Greater China [1]. Group 2: Market Trends - There has been a notable increase in business development collaborations between multinational pharmaceutical companies and local innovative drug firms since the end of 2023, with several prominent projects emerging this year [1][2]. - The innovative drug sector in Hong Kong is experiencing a valuation expansion that may be stronger than that in A-shares, driven by higher R&D expenditure and overseas revenue proportions [3]. Group 3: Financial Performance - The overall net profit growth of the Hong Kong innovative drug sector has consistently outpaced that of A-shares since the first half of 2023, suggesting a favorable outlook for profitability [3]. - The sector is more sensitive to U.S. Treasury rates and benefits from overseas liquidity easing, which could enhance valuation levels [4]. - Companies in the Hong Kong innovative drug sector are perceived to have better cost-performance advantages, indicating greater potential for valuation elasticity [4]. Group 4: Company Developments - Heptares Therapeutics has entered a share subscription agreement with AstraZeneca, with a subscription price of $1.38 per share, representing a 37.2% premium over the closing price on the agreement date [6]. - Federal Pharmaceuticals has signed an exclusive licensing agreement with Novo Nordisk for UBT251, a triple agonist in early clinical development, with potential payments totaling up to $1.8 billion [7][8]. - Akeso reported a significant revenue increase of 4765.6% to approximately 156 million yuan, driven by a milestone collaboration agreement worth 900 million yuan [8]. - Hutchison China MediTech received conditional approval for its drug Tazemetostat in China, marking its first national regulatory approval [9]. - China Biologic Products announced positive interim results for its innovative drug Culmerciclib in a Phase III trial for breast cancer, with plans to submit a marketing application soon [10].

Core Insights - Heng Rui Medicine has entered into a significant licensing agreement with Merck for its oral small molecule project targeting lipoprotein(a), with an upfront payment of $200 million and potential milestone payments up to $1.77 billion [3][4] - The Hong Kong Stock Connect Innovation Drug ETF (159570) has seen substantial inflows, with net subscriptions exceeding 240 million yuan and a total of over 800 million yuan in the last 60 days, indicating strong investor interest in innovative drug companies [4][6] - The trend of Chinese innovative drug companies expanding overseas is accelerating, with at least 262 license-out transactions expected from 2020 to 2024, totaling over $150 billion [4][5] Company Developments - Heng Rui Medicine's licensing deal with Merck includes exclusive rights for global development, production, and commercialization outside Greater China for the drug HRS-5346 [3][4] - Other companies like United Pharmaceuticals and Innovent Biologics have also secured significant licensing agreements, indicating a broader trend in the industry [3][5] - The recent performance of stocks within the Hong Kong Stock Connect Innovation Drug ETF shows a mixed picture, with notable gains from companies like 3SBio and declines from companies like Yunnan Baiyao [3][4] Market Trends - The Hong Kong Stock Connect Innovation Drug ETF has reached a new high in shares, reflecting a doubling in size over the past month, driven by increased investor confidence [4][6] - The overall market for innovative drugs is expected to benefit from AI advancements, improved financing conditions, and potential fiscal support, which could enhance profit margins for these companies [4][6] - The ETF's composition highlights a strong focus on leading companies in the innovative drug sector, with over 68% of its weight in the top ten holdings [6][7]

Financial Performance - The total revenue for the year 2024 was approximately RMB 13,758.9 million, showing a slight increase of 0.1% compared to 2023[3]. - The profit attributable to the company's owners for the year was RMB 2,659.7 million, reflecting a decrease of 1.5% year-on-year[4]. - The basic earnings per share for the year were RMB 146.39, down 1.5% from the previous year[3]. - Gross profit decreased to RMB 6,082,391 thousand in 2024 from RMB 6,334,837 thousand in 2023, reflecting a decline of about 3.98%[13]. - The company reported a net profit of RMB 2,657,821 thousand for 2024, down from RMB 2,700,845 thousand in 2023, indicating a decrease of approximately 1.6%[13]. - The revenue breakdown for 2024 includes RMB 2,658,691 thousand from intermediate products, RMB 6,372,683 thousand from active pharmaceutical ingredients, and RMB 4,727,563 thousand from formulation products[30]. - The segment profit before R&D expenses for 2024 was RMB 4,009,219 thousand, compared to RMB 4,112,034 thousand in 2023, indicating a decrease of about 2.5%[30][32]. - R&D expenses for 2024 totaled RMB 890,757 thousand, an increase from RMB 757,248 thousand in 2023, reflecting a rise of approximately 17.6%[34]. - The company reported a pre-tax profit of RMB 3,288,898 thousand for 2024, compared to RMB 3,344,148 thousand in 2023, showing a decrease of about 1.65%[32]. - The total other income for 2024 was RMB 356,929 thousand, significantly higher than RMB 212,475 thousand in 2023, representing an increase of about 67.9%[33]. - The company’s external customer revenue from the Chinese market was RMB 11,115,585 thousand in 2024, slightly down from RMB 11,124,265 thousand in 2023, a decrease of about 0.08%[32]. - The company’s net profit attributable to shareholders was RMB 2,659,700,000, a decrease of 1.5% year-on-year, with earnings per share at RMB 146.39[62]. - The company’s formulation product segment saw a significant profit decline of 47.0%, primarily due to price reductions from national drug procurement policies[62]. Dividends and Shareholder Returns - The company declared a total annual dividend of RMB 56.0 per share, representing a 7.7% increase compared to the previous year[3]. - The total dividend declared for 2024 was RMB 726,733,000, consistent with the previous year's total of RMB 726,811,000, indicating stability in dividend distribution[39]. Assets and Liabilities - The total assets increased to RMB 17,060,503 thousand in 2024 from RMB 14,390,448 thousand in 2023, marking a growth of about 18.6%[14]. - Non-current assets rose to RMB 9,762,356 thousand in 2024, compared to RMB 7,229,979 thousand in 2023, an increase of approximately 35%[14]. - The company’s total assets rose to approximately RMB 25,833,100,000 from RMB 21,017,200,000 in 2023, while total liabilities increased to RMB 11,397,800,000 from RMB 8,269,600,000[65]. - The company’s accounts payable for trade and supplier financing arrangements amounted to RMB 2,088,785,000, a decrease from RMB 2,238,152,000 in 2023[13]. Investments and Expenditures - The company invested approximately RMB 2,858,081,000 in property, plant, and equipment in 2024, significantly higher than RMB 1,143,439,000 in 2023, representing an increase of about 150%[41]. - The company has committed to capital expenditures of RMB 2,147,126,000 for property, plant, and equipment that have been contracted but not yet provided for in the financial statements[45]. - The company recorded a depreciation expense of RMB 579,883,000 for property, plant, and equipment in 2024, compared to RMB 536,303,000 in 2023, reflecting an increase of about 8.1%[39]. Research and Development - The company has 8 Class 1 new drug projects in clinical stages, including several high-value products[5]. - The company is actively pursuing new drug projects for overseas licensing to provide comprehensive treatment options globally[5]. - The company has established a comprehensive R&D system, including multiple platforms for biological, chemical, and innovative drug development[59]. - The company invested approximately RMB 985,500,000 in drug research and development, with R&D expenses increasing by 21.9% year-on-year[59]. - The company has 45 new human drug products in development, including 22 Class 1 new drugs focusing on endocrine, metabolism, autoimmune, ophthalmology, and anti-infection fields[59]. Market Expansion and Partnerships - The company has secured 6 overseas registrations for its animal health products and is expanding its international market presence[8]. - Strategic partnerships have been formed with various domestic and international partners to enhance the company's global footprint[8]. - The company achieved record overseas revenue in its intermediates and raw materials business, enhancing its international brand recognition[9]. Corporate Governance and Management - The company has adopted and complied with the corporate governance code as per the Stock Exchange Listing Rules, with some deviations noted[72]. - There is currently no Chief Executive Officer, and the company plans to appoint one at an appropriate time[73]. - The audit committee, consisting of three independent non-executive directors, reviewed the consolidated financial statements for the year ending December 31, 2024[75]. - The board of directors includes six executive directors and three independent non-executive directors as of the announcement date[77]. Compliance and Accounting Standards - The group has adopted revised Hong Kong Financial Reporting Standards effective from January 1, 2024, including HKFRS 16 regarding lease liabilities and HKAS 1 for classifying liabilities as current or non-current[17]. - The adoption of these amendments did not have a significant impact on the consolidated financial statements[22]. - The group has not early adopted any new or revised Hong Kong Financial Reporting Standards that have been issued but are not yet effective[23]. Legal Matters - The group is involved in a lawsuit to recover approximately RMB 340,000,000 in unpaid receivables, with a court ruling on December 28, 2024, ordering Chengdu Evergrande to pay approximately RMB 136,300,000[69].

Core Viewpoint - Despite announcing a collaboration with Novo Nordisk for the weight loss drug UBT251, the stock price of Federated Pharmaceutical fell significantly due to disappointing financial results for 2024, which showed a decline in net profit [3][4]. Financial Performance - Federated Pharmaceutical reported a revenue of 13.76 billion RMB for 2024, a slight increase of 0.14% year-on-year [7]. - The company's net profit attributable to shareholders was 2.66 billion RMB, reflecting a decrease of 1.54% compared to the previous year [7]. - The earnings per share decreased by 1.5% to 146.39 RMB [5]. Business Segments - Revenue from intermediate products increased by 1.8%, while revenue from raw materials and formulation products decreased by 0.5% and 5.9%, respectively [7]. - The significant decline in the formulation business was attributed to price reductions due to national drug procurement policies, alongside a 26.6% increase in R&D expenses for formulation products [7]. Key Product Developments - The UBT251 drug, developed by Federated Pharmaceutical, is currently in early clinical development and aims to treat obesity and type 2 diabetes [3][9]. - The company is the first in China and the second globally to have a long-acting GLP-1/GIP/GCG tri-target agonist approved for clinical trials using chemical synthesis methods [9]. - Sales of diabetes products reached 1.25 billion RMB in 2024, marking a 9.5% increase year-on-year, with insulin product sales benefiting from a significant increase in procurement volume [8].

Core Viewpoint - Novo Nordisk has made a significant investment of $2 billion to acquire global rights for the development, manufacturing, and commercialization of UBT251 from United Pharmaceuticals, indicating its ambition in the weight loss sector beyond its existing product, semaglutide [1][2][3]. Group 1: Investment and Agreements - Novo Nordisk entered into an exclusive licensing agreement with United Pharmaceuticals, acquiring rights to UBT251, a triple agonist targeting GLP-1, GIP, and glucagon receptors, which is currently in early clinical development [2][3]. - The agreement allows Novo Nordisk to develop and commercialize UBT251 globally, excluding mainland China and certain regions, with United Pharmaceuticals retaining rights in those areas [2][3]. - United Pharmaceuticals is set to receive an upfront payment of $200 million and up to $1.8 billion in potential milestone payments based on development and sales achievements [2][3]. Group 2: Clinical Data and Product Potential - UBT251 has shown superior efficacy in preclinical models for kidney damage compared to semaglutide, particularly in improving markers of renal injury [3][4]. - The drug is being tested for a wide range of indications, including obesity, type 2 diabetes, and chronic kidney disease, with ongoing clinical trials in various populations [3][4]. Group 3: Market Landscape and Competition - The global anti-obesity drug market is projected to reach $100 billion by 2030, attracting numerous competitors [5][6]. - Novo Nordisk's semaglutide has established a leading position in the market, with significant sales figures, while other companies like Eli Lilly and Merck are also developing competing products [5][6][7]. - Recent collaborations by major pharmaceutical companies, such as Roche and AbbVie, indicate a growing interest in long-acting insulin analogs and other innovative treatments for obesity [6][7].

创下新高！一款国产减肥药卖了20亿美元 当下最火热的降糖减重领域又现重磅交易。 3月24日晚间，国内药企联邦制药宣布与跨国药企诺和诺德签订独家许可协议。后者将获得前者三 靶点GLP-1药物UBT251在海外的开发、制造和商业化权益。 而在"主战场"GLP-1药物上，诺和诺德和礼来两大龙头缠斗已久，两者分别推出了司美格鲁肽、替 尔泊肽两大明星产品，用于2型糖尿病和减重。 这也不断推高了该领域的竞争难度，并使GLP-1药物开发从日制剂做到周制剂，从注射到口服，从 单靶点到多靶点产品，追求降糖减重效果的同时，平衡药物安全性、耐受性，提高患者依从性，并探索 更多方面的临床获益。 2024年，司美格鲁肽、替尔泊肽全球销售额分别为293亿美元、165亿美元，前者直逼当年全球销售 额"药王"的水平。但在后续管线上，诺和诺德此时显得较为弱势。 根据协议，联邦制药将有资格获得2亿美元预付款、最高18亿美元的潜在里程碑付款，及相应分层 销售提成。 不过3月25日开盘，联邦制药股价一路大跌，收盘价报14.680港元/股，跌11.78%，当下市值267亿 港元。 消息面上，除前述交易外，联邦制药还公布了2024年业绩。当期，公司营收 ...

Core Insights - The article discusses the rising valuation of companies involved in the development of weight loss drugs, particularly focusing on the GLP-1 receptor agonist, Semaglutide, which has gained popularity for its weight loss effects and is part of a national initiative for weight management in China [1][2][6]. Company Insights - Zhifei Biological Products has plans to acquire Chuan'an Biotechnology, which is positioned to benefit from the growing market for Semaglutide and related drugs [7][8]. - Chuan'an Biotechnology is in the lead for the first batch of generic Semaglutide drugs, with several candidates in various stages of clinical trials, indicating a strong pipeline for future growth [7][8]. - Zhifei Biological's strategy emphasizes self-research and development, alongside partnerships and investments, to enhance its innovation capabilities and expand into the metabolic disease sector [8]. Industry Insights - The market for Semaglutide in China is projected to grow significantly, from 2.5 billion yuan in 2022 to 43.9 billion yuan by 2032, reflecting a compound annual growth rate (CAGR) of 33% [6]. - The obesity rate in China is expected to reach 65.3% by 2030, and the number of type 2 diabetes patients is projected to hit 140 million by 2032, creating a substantial market opportunity for weight loss and diabetes management drugs [6][7]. - The patent for Semaglutide in China will expire in 2026, allowing companies that can launch generics to capture significant market share [7].

Financial Performance - The total revenue for the year 2024 was approximately RMB 13,758.9 million, showing a slight increase of 0.1% compared to 2023[3] - The profit attributable to the company's owners for 2024 was RMB 2,659.7 million, reflecting a decrease of 1.5% year-on-year[3] - The basic earnings per share for 2024 were RMB 146.39, down 1.5% from the previous year[3] - The gross profit for 2024 was RMB 6,082,391 thousand, down from RMB 6,334,837 thousand in 2023, indicating a decrease of about 3.98%[14] - The company achieved a net profit of RMB 2,657,821 thousand for 2024, compared to RMB 2,700,845 thousand in 2023, reflecting a decline of approximately 1.6%[14] - The company’s net profit attributable to shareholders for 2024 was RMB 2,659,704,000, a slight decrease from RMB 2,701,350,000 in 2023, representing a decline of about 1.5%[46] - The company reported a pre-tax profit of RMB 3,288,898 thousand for the fiscal year ending December 31, 2024, compared to RMB 3,344,148 thousand in 2023, reflecting a decrease of about 1.66%[35] - The total tax expenses for 2024 amounted to RMB 631,077,000, compared to RMB 643,303,000 in 2023, reflecting a decrease of approximately 1.9%[41] Dividends and Shareholder Returns - The company declared a total annual dividend of RMB 56.0 per share, an increase of 7.7% compared to the previous year, with a payout ratio of 38.3%[5] - The company declared a total dividend of RMB 726,733,000 for the year ending December 31, 2024, slightly lower than RMB 726,811,000 in 2023[44] Research and Development - The company has 8 Class 1 new drug projects in clinical stages, including several high-value products, and is actively advancing its R&D efforts[6] - The company has entered into an exclusive licensing agreement with Novo Nordisk for the self-developed product UBT251, marking a significant milestone in its R&D progress[12] - R&D expenses for the year amounted to RMB 890,757 thousand, up from RMB 757,248 thousand in 2023, indicating an increase of approximately 17.6%[38] - The company invested approximately RMB 985,500,000 in drug research and development, with R&D expenses increasing by 21.9% year-on-year[68] - The company has established a comprehensive R&D system, including multiple platforms for biological, chemical, and innovative drug research, as well as clinical studies and external collaborations[68] - The company has initiated several key clinical trials for new drugs, including TUL01101 and UBT251, with significant milestones achieved in 2024[69] Market Expansion and Strategic Initiatives - The company has signed a strategic cooperation agreement with New Zealand Riverland Foods Ltd. to enter the high-end pet food market in China[9] - The company has obtained 6 overseas registration approvals for its animal health products and aims to expand its market presence in Southeast Asia, Latin America, the Middle East, and Africa[9] - The company achieved record overseas revenue in its intermediates and raw materials business, enhancing its global brand recognition[10] - The company plans to enhance its core industry advantages and strengthen vertical integration while optimizing its diversified business layout and resource allocation to accelerate international market expansion[12] - The company aims to maintain its leading position in the industry amidst ongoing healthcare reforms and demographic changes in China, which are expected to drive market growth[12] Financial Position and Assets - The total assets as of December 31, 2024, amounted to RMB 17,060,503 thousand, an increase from RMB 14,390,448 thousand in 2023, showing a growth of about 18.6%[15] - The company’s cash and cash equivalents rose to RMB 6,329,841 thousand in 2024, up from RMB 4,261,989 thousand in 2023, marking an increase of approximately 48.5%[15] - The company’s total equity increased to RMB 14,435,240 thousand in 2024 from RMB 12,747,618 thousand in 2023, reflecting a growth of about 13.2%[17] - The company’s total assets increased to approximately RMB 25,833,100,000, compared to RMB 21,017,200,000 in 2023, while total liabilities rose to RMB 11,397,800,000 from RMB 8,269,600,000[74] Operational Efficiency - The company reported a decrease in selling and distribution expenses to RMB 1,402,483 thousand in 2024 from RMB 1,593,799 thousand in 2023, a reduction of approximately 11.97%[14] - The company’s financial costs decreased to RMB 34,958 thousand in 2024 from RMB 66,896 thousand in 2023, a reduction of approximately 47.8%[40] - The company’s employee costs, including director remuneration, rose to RMB 1,827,993,000 in 2024 from RMB 1,648,745,000 in 2023, an increase of about 10.9%[44] - The inventory cost recognized in expenses for 2024 was RMB 7,692,205,000, compared to RMB 7,361,854,000 in 2023, representing an increase of approximately 4.5%[44] Corporate Governance and Compliance - The group has adopted revised Hong Kong Financial Reporting Standards effective from January 1, 2024, which include HKFRS 16 regarding lease liabilities and HKAS 1 for classifying liabilities as current or non-current[20] - The group has retrospectively applied new accounting policies for classifying liabilities as current or non-current, with no significant impact on the consolidated financial statements[23] - The company has adopted and complied with the corporate governance code as per the Stock Exchange Listing Rules, with a commitment to high standards of corporate governance[81] - There is currently no Chief Executive Officer, and the company plans to appoint one at an appropriate time[82] - The audit committee, consisting of three independent non-executive directors, reviewed the consolidated financial statements for the year ending December 31, 2024[84] Legal Matters - The company is involved in a lawsuit to recover approximately RMB 340,000,000 in unpaid receivables from Chengdu Evergrande, with a court ruling on December 18, 2024, ordering payment of approximately RMB 136,300,000[78]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [2][11]. Core Insights - New technology platforms are increasingly favored by multinational corporations (MNCs), leading to earlier collaboration opportunities. A notable example is the global strategic partnership between Heptares Therapeutics and AstraZeneca, which includes a $105 million equity investment [3]. - The weight loss market is seeing multiple business developments (BD) materialize, with significant sales growth reported by Novo Nordisk and Eli Lilly. Novo Nordisk's core products generated approximately $27.94 billion in sales, while Eli Lilly's tirzepatide saw a 124% year-on-year increase in sales to $11.54 billion [5]. - Progress in universal CAR-T and solid tumor cell therapies is ongoing, with global CAR-T sales projected at approximately $4.53 billion in 2024. Chinese companies are also participating in this market, with three domestic CAR-T products approved for sale [6]. - The CRO (Contract Research Organization) environment may experience changes, with potential supply flexibility due to the easing of U.S. bioterrorism law concerns. This could enhance the competitiveness of Chinese CROs [7]. - The active pharmaceutical ingredient (API) sector is exploring new applications, particularly in the nicotine tobacco production sector, leveraging synthetic biology technologies [8]. - Major hospitals are launching specialized AI models, indicating a rising trend in the integration of AI in healthcare, with collaborations between tech companies and healthcare providers [10]. Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.88 percentage points over the past week, ranking 20th among 31 primary industry indices [20]. 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector's index has a current PE (TTM) of 30.95, which is below the five-year historical average of 32.98 [36]. 3. Recent Research Achievements - The research team has published several in-depth reports on various pharmaceutical sectors, highlighting trends such as the growth of blood products and the impact of policy support on inhalation drug industries [40]. 4. Important Industry Policies and News - Recent policy changes include the National Medical Products Administration's (NMPA) decision to abolish certain medical device standards to optimize the regulatory framework [42]. - Significant industry news includes the approval of several new drug applications and clinical trials by the NMPA, indicating a robust pipeline for pharmaceutical innovation [44][46].

2025 年 3 月 14 日 星期五 每日大市点评 3 月 13 日，港股大盘连续第二天震荡，恒生指数最终微跌 138 点或 0.6%，收报 23,462 点。这是自今年 1 月 23 日以来第 一次连续两天阴烛下跌，说明港股的运行节奏或有所改变。恒生科指下跌 1.7%，收报 5,747 点。大市成交金额进一步下 降至 2,338 亿港元，港股通净流入 54.6 亿港元。港股第一波的估值已基本修复到位，大市成交下降也反映投资者开始谨 慎，甚至有获利的倾向，也有部分资金回流美股博反弹。另外，美国对所有进口钢铝加征 25%关税，不设豁免，全球地缘 政治风险也有所升温，增加了港股的观望情绪。接下来，中国将公布 1-2 月的消费、投资、地产及信贷等重磅经济数据， 将是市场关注的焦点。港股整体估值的进一步修复需要宏观经济的持续改善，推动企业盈利见底回升。昨日盘面行情倾 向保守及防御为主，内银、石油、电讯、煤炭及公用事业股逆市上升，顺周期板块普遍下跌。除机器人概念股保持较强 态势外，大部分 AI+股份近期跑输恒生指数，股价无法升越 2 月中的高点。从这个方度看，港股的 AI 需要休整，消化估 值。我们认为当前要关注低估 ...